Maitri Health Technologies Corp. announced it has signed a distribution agreement to offer a highly sensitive and accurate COVID-19 polymerase chain reaction ("PCR") test as part of its comprehensive offering of personal protective equipment ("PPE") and technology. Maitri has partnered with DiaCarta Inc. ("DiaCarta"), a California-based precision molecular diagnostics company with a global reputation in genomics and oncology testing. DiaCarta leveraged its diagnostic expertise to develop QuantiVirus, now certified in multiple countries and continents around the world. Maitri's partnership with DiaCarta includes an international distribution agreement, currently in Mexico and Canada. With US FDA, EUA and Mexican Cofepris authorizations in place, DiaCarta is currently under evaluation with Health Canada for approval. The COVID-19 PCR test kits join Maitri's extensive suite of PPE. 3D masks, patent-pending face shields, sanitizers and disinfectants - all integrated and supported by technology for improved tracking and tracing - help provide safer, more protected workplaces and communities.